Skip to content

Study · Systematic review · n = 1,335 · 2023

7 results

Cerebrolysin for acute ischaemic stroke.

Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K

The Cochrane database of systematic reviews11 Oct 2023Cited by 15 (Europe PMC)

PMID37818733 (opens in a new tab)PMCIDPMC10565895 (opens in a new tab)DOI10.1002/14651858.cd007026.pub7 (opens in a new tab)PepBankPUB-37818733
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In acute ischaemic stroke, Cerebrolysin probably changed serious adverse event risk little versus placebo or no treatment.

    In plain wordsIn stroke patients, Cerebrolysin probably changed serious adverse event risk little compared with placebo or no treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAny serious adverse event
    Study

    n = 1,335

    Comparator
    Placebo or no treatment
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    1.16 ratio
    Serious adverse events
    95% confidence interval for risk ratio of total number of people with serious adverse events
    0.81 to 1.66 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; total number of people with serious adverse events

    Source sentences

    Summary
    Serious adverse events (SAEs): Cerebrolysin probably results in little to no difference in the total number of people with SAEs (RR 1.16, 95% CI 0.81 to 1.66; 3 trials, 1335 participants; moderate-certainty evidence).
    1 context sentence
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.
  2. 02HumanSystematic reviewSafety outcome

    In acute ischaemic stroke, fatal serious adverse event risk with Cerebrolysin did not differ significantly from controls.

    In plain wordsIn stroke patients, fatal serious adverse event risk with Cerebrolysin did not differ significantly from controls.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeFatal serious adverse events
    Study

    n = 1,335

    Comparator
    Placebo or no treatment
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.9 ratio
    Fatal serious adverse events
    95% confidence interval for risk ratio of fatal serious adverse events
    0.59 to 1.38 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; fatal serious adverse events

    Source sentences

    Summary
    This comprised fatal SAEs (RR 0.90, 95% CI 0.59 to 1.38; 3 trials, 1335 participants; moderate-certainty evidence)
    1 context sentence
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.
  3. 03HumanSystematic reviewSafety outcome

    In acute ischaemic stroke, Cerebrolysin was associated with more non-fatal serious adverse events than placebo or no treatment (moderate-certainty evidence).

    In plain wordsIn stroke patients, Cerebrolysin was linked to more non-fatal serious adverse events than placebo or no treatment, based on moderate-certainty evidence.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNon-fatal serious adverse events
    Study

    n = 1,335

    Comparator
    Placebo or no treatment
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    2.39 ratio
    Non-fatal serious adverse events
    95% confidence interval for risk ratio of total number of people with non-fatal serious adverse events
    1.1 to 5.23 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; total number of people with non-fatal serious adverse events

    Source sentences

    Summary
    an increase in the total number of people with non-fatal SAEs (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1335 participants; moderate-certainty evidence).
    1 context sentence
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.
  4. 04HumanSystematic reviewSafety outcome

    In acute ischaemic stroke, the Cerebrolysin dosing subgroup showed a more prominent increase in non-fatal serious adverse events versus controls.

    In plain wordsIn stroke patients, this Cerebrolysin dosing subgroup showed a more prominent increase in non-fatal serious adverse events compared with controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNon-fatal serious adverse events at 30 mL for 10 days
    Study

    n = 1,189

    Comparator
    Placebo or no treatment
    Outcome group
    Adverse events · Whole body
    Studied dose
    30 mL · 10 daysAs given in this study (human).

    Measurements

    Risk ratio
    2.87 ratio
    Non-fatal serious adverse events
    95% confidence interval for risk ratio of non-fatal serious adverse events; dosing subgroup of 30 mL for 10 days
    1.24 to 6.69 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; non-fatal serious adverse events; dosing subgroup of 30 mL for 10 days

    Source sentences

    Summary
    In the subgroup of dosing schedule 30 mL for 10 days (cumulative dose 300 mL), the increase was more prominent (RR 2.87, 95% CI 1.24 to 6.69; 2 trials, 1189 participants).
    2 context sentences
    Summary · context
    an increase in the total number of people with non-fatal SAEs (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1335 participants; moderate-certainty evidence).
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.

Studies that did not test the peptide alone3

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 05HumanNot a test of Cerebrolysin aloneSystematic reviewSafety outcome

    In acute ischaemic stroke, pooled Cerebrolysin or similar mixtures may change non-death attrition little versus placebo or no treatment, with very uncertain evidence.

    In plain wordsIn stroke patients, pooled Cerebrolysin or similar mixtures may change non-death attrition little versus controls, but evidence is very uncertain.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeNon-death attrition
    Study

    n = 1,689

    Comparator
    Placebo or no treatment
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body

    Measurements

    Risk ratio
    0.72 ratio
    Non-death attrition
    95% confidence interval for risk ratio of non-death attrition
    0.38 to 1.39 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; non-death attrition

    Source sentences

    Summary
    Non-death attrition (secondary outcome): Cerebrolysin or similar peptide mixtures may result in little to no difference in non-death attrition, but the evidence is very uncertain, with a considerable level of heterogeneity (RR 0.72, 95% CI 0.38 to 1.39; 6 trials, 1689 participants; very low-certainty evidence).
    1 context sentence
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 06HumanNot a test of Cerebrolysin aloneSystematic reviewEfficacy outcome

    In acute ischaemic stroke, pooled Cerebrolysin or Cortexin probably produced little to no difference in all-cause death versus placebo or no treatment.

    In plain wordsIn stroke patients, pooled Cerebrolysin or Cortexin probably changed death risk little compared with placebo or no treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAll-cause death
    Study

    n = 1,689

    Comparator
    Placebo or no treatment
    Outcome group
    Mortality · Whole body

    Measurements

    Risk ratio
    0.96 ratio
    All-cause death
    95% confidence interval for risk ratio of all-cause death
    0.65 to 1.41 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; all-cause death

    Source sentences

    Summary
    All-cause death: Cerebrolysin or Cortexin probably result in little to no difference in all-cause death (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.65 to 1.41; 6 trials, 1689 participants; moderate-certainty evidence).
    1 context sentence
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 07HumanNot a test of Cerebrolysin aloneSystematic reviewSafety outcome

    In acute ischaemic stroke, pooled Cerebrolysin or similar mixtures may change adverse event risk little versus placebo or no treatment.

    In plain wordsIn stroke patients, pooled Cerebrolysin or similar mixtures may change adverse event risk little compared with placebo or no treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeAny adverse event
    Study

    n = 1,607

    Comparator
    Placebo or no treatment
    Outcome group
    Adverse events · Whole body

    Measurements

    Risk ratio
    1.03 ratio
    Any adverse event
    95% confidence interval for risk ratio of total number of people with adverse events
    0.92 to 1.14 ratio
    Cerebrolysin or the stated pooled peptide mixtures versus placebo or no treatment; total number of people with adverse events

    Source sentences

    Summary
    Total number of people with adverse events: Cerebrolysin or similar peptide mixtures may result in little to no difference in the total number of people with adverse events (RR 1.03, 95% CI 0.92 to 1.14; 4 trials, 1607 participants; low-certainty evidence).
    1 context sentence
    Summary · context
    Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin-like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.